235 related articles for article (PubMed ID: 25136960)
1. Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2.
Makarević J; Rutz J; Juengel E; Kaulfuss S; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
PLoS One; 2014; 9(8):e105590. PubMed ID: 25136960
[TBL] [Abstract][Full Text] [Related]
2. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
[TBL] [Abstract][Full Text] [Related]
3. Amygdalin inhibits the growth of renal cell carcinoma cells in vitro.
Juengel E; Thomas A; Rutz J; Makarevic J; Tsaur I; Nelson K; Haferkamp A; Blaheta RA
Int J Mol Med; 2016 Feb; 37(2):526-32. PubMed ID: 26709398
[TBL] [Abstract][Full Text] [Related]
4. Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells.
Tsaur I; Thomas A; Monecke M; Zugelder M; Rutz J; Grein T; Maxeiner S; Xie H; Chun FK; Rothweiler F; Cinatl J; Michaelis M; Haferkamp A; Blaheta RA
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804883
[TBL] [Abstract][Full Text] [Related]
5. Manganese chloride-induced G0/G1 and S phase arrest in A549 cells.
Zhao P; Zhong W; Ying X; Yuan Z; Fu J; Zhou Z
Toxicology; 2008 Aug; 250(1):39-46. PubMed ID: 18577415
[TBL] [Abstract][Full Text] [Related]
6. Amygdalin delays cell cycle progression and blocks growth of prostate cancer cells in vitro.
Makarević J; Tsaur I; Juengel E; Borgmann H; Nelson K; Thomas C; Bartsch G; Haferkamp A; Blaheta RA
Life Sci; 2016 Feb; 147():137-42. PubMed ID: 26827990
[TBL] [Abstract][Full Text] [Related]
7. Amygdalin influences bladder cancer cell adhesion and invasion in vitro.
Makarević J; Rutz J; Juengel E; Kaulfuss S; Tsaur I; Nelson K; Pfitzenmaier J; Haferkamp A; Blaheta RA
PLoS One; 2014; 9(10):e110244. PubMed ID: 25333694
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
9. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
10. Zedoarondiol Inhibits Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cells Proliferation via Regulating AMP-Activated Protein Kinase Signaling Pathway.
Mao H; Tao T; Song D; Liu M; Wang X; Liu X; Shi D
Cell Physiol Biochem; 2016; 40(6):1506-1520. PubMed ID: 27997894
[TBL] [Abstract][Full Text] [Related]
11. Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells.
Justin S; Rutz J; Maxeiner S; Chun FK; Juengel E; Blaheta RA
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32512849
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
13. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1 phase cell cycle arrest: persistent p27(Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway.
Li A; Wang J; Wu M; Zhang X; Zhang H
Eur J Pharmacol; 2015 Jan; 747():71-87. PubMed ID: 25498792
[TBL] [Abstract][Full Text] [Related]
14. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
15. Fargesin Inhibits EGF-Induced Cell Transformation and Colon Cancer Cell Growth by Suppression of CDK2/Cyclin E Signaling Pathway.
Lee GE; Lee CJ; An HJ; Kang HC; Lee HS; Lee JY; Oh SR; Cho SJ; Kim DJ; Cho YY
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669811
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effects of a novel benzonaphthofurandione derivative (8e) on the human colon cancer cells in vitro and in vivo through cell cycle arrest accompanied with the modulation of EGFR and mTOR signaling.
Chung HJ; Rhee HK; Lee SK; Park Choo HY
Chem Biol Interact; 2011 Aug; 193(1):43-9. PubMed ID: 21600193
[TBL] [Abstract][Full Text] [Related]
17. HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro.
Vallo S; Xi W; Hudak L; Juengel E; Tsaur I; Wiesner C; Haferkamp A; Blaheta RA
Anticancer Drugs; 2011 Nov; 22(10):1002-9. PubMed ID: 21822119
[TBL] [Abstract][Full Text] [Related]
18. Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Rutz J; Maxeiner S; Grein T; Sonnenburg M; Khadir SE; Makhatelashvili N; Mann J; Xie H; Cinatl J; Thomas A; Chun FK; Haferkamp A; Blaheta RA; Tsaur I
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232303
[TBL] [Abstract][Full Text] [Related]
19. Bufalin induces G0/G1 phase arrest through inhibiting the levels of cyclin D, cyclin E, CDK2 and CDK4, and triggers apoptosis via mitochondrial signaling pathway in T24 human bladder cancer cells.
Huang WW; Yang JS; Pai SJ; Wu PP; Chang SJ; Chueh FS; Fan MJ; Chiou SM; Kuo HM; Yeh CC; Chen PY; Tsuzuki M; Chung JG
Mutat Res; 2012 Apr; 732(1-2):26-33. PubMed ID: 22285700
[TBL] [Abstract][Full Text] [Related]
20. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
